Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Gang Shen (Author), Lei Shi (Author), Xin Tian (Author), Depei Huang (Author), Hao Chen (Author), Chan Gao (Author), Xudong Shen (Author), Hushan Zhang (Author)
Format: Book
Published: Frontiers Media S.A., 2021-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available